期刊文献+

调强放疗联合腔内后装放疗治疗晚期宫颈癌的临床研究 被引量:2

Clinical research on intensity modulated radiation therapy combined with afterloading radiotherapy for the treatment of advanced cervical cancer
下载PDF
导出
摘要 目的探讨调强放疗联合腔内后装放疗治疗晚期宫颈癌的临床效果。方法选取我院收治的晚期宫颈癌患者48例,随机均分为对照组和实验组,对照组行常规放疗联合腔内后装放疗治疗,实验组行调强放疗(IMRT)联合腔内后装放疗治疗。观察比较两组患者放疗疗效及骨髓抑制、放射性膀胱炎、放射性直肠炎、放射性皮炎等不良反应发生率。结果实验组患者放疗总缓解率为91.7%(22/24),显著高于对照组的66.7%(16/24)(P〈0.05)。实验组患者骨髓抑制、放射性膀胱炎、放射性直肠炎等并发症发生率分别为29.2%,33.3%,0.0%,均显著低于对照组患者(P〈0.05)。实验组患者放射性皮炎发生率为O.0%,对照组为16.7%,组间比较差异无统计学意义(P〉0.05)。结论调强放疗联合腔内后装放疗治疗晚期宫颈癌临床疗效确切,能有效减少并发症的发生,值得广泛推广使用。 Objective To investigate the clinical effect of intensity modulated radiation therapy (IMRT) combined with afterloading radiotherapy for the treatment of advanced cervical cancer. Methods 48 patients with advanced cervical cancer were randomly divided into control group (treated with conventional radiotherapy) and experimental group (treated with IMRT combined with afterloading radiotherapy). The radiotherapy effect and incidence of complications of two groups were compared. Results The total response rate of experimental group was 91.7%, which was significantly higher than 66.7% of control group (P 〈 0.05). The incidence of complications of experimental group was lower than that of control group. Conclusion IMRTcombined with afterloading radiotherapy is effective for advanced cervical cancer. It is worthy of wide use and promotion.
作者 陈婷
出处 《国际医药卫生导报》 2014年第5期620-622,共3页 International Medicine and Health Guidance News
关键词 调强放疗 腔内后装放疗 晚期宫颈癌 Intensity modulated radiation therapy (IMRT) Afterloading radiotherapy Advancedcervical cancer
  • 相关文献

参考文献8

二级参考文献47

  • 1邓守恒,蔡晓军,李林均,李芳,陈萍,徐华,曹凤军.三维适形放疗联合^(192)Ir腔内后装治疗中晚期宫颈癌[J].郧阳医学院学报,2010,29(5):432-434. 被引量:13
  • 2赵湘,魏莹.CD44v7/8基因表达与宫颈癌关系的探讨[J].中国实用妇科与产科杂志,2005,21(6):369-370. 被引量:1
  • 3孙帅,张福泉.宫颈癌的调强放射治疗[J].肿瘤学杂志,2006,12(5):377-381. 被引量:11
  • 4余健,张国楠,樊英.同步放化疗治疗中晚期宫颈癌50例临床疗效观察[J].实用妇产科杂志,2007,23(5):287-289. 被引量:74
  • 5EIFEL P J, WINTER K, MORRIS M, et al. Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aoritc irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01 [J]. J Clin Oncol, 2004, 22(5): 872-880.
  • 6GREEN J A, KIRWAN J W, TIEMEY J F, et al. Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic and meta- analysis[J]. Lancet, 2001, 358(9): 781-786.
  • 7YAMADA H, UCHIDA N, MAEKAWA R, et al. Sequence dependent antitumor efficacy of combination chemotherapy with nedaplatin, a newly developed platinum, and palitaxel[J]. Cancer Lett, 2001, 172(1): 1 7-25.
  • 8SHIRAI T, HIROSE T, NODA M, et al. Phase II study of the combination of gemcitabine and nedaplatin for advanced non-small-cell lung cancer[J]. Lung Cancer, 2006, 52(2): 181-187.
  • 9Dimopoulos JC, Lang S, Kirisits C, et al. Dose Volume his- togram parameters and local tumor control in magnetic reso- nance Image-Guided cervical cancer brachytherapy[J]. Int J Radiat Oncol Biol Phys, 2009,75 (1) : 56-63.
  • 10Tiemey J. Neoadjuvant chemotherapy for locally advanced cervical cancer: a systematic review and meta-analysis of individual patient data from 21 randomised trials[ J]. Eur J Cancer, 2003,39 ( 17 ) : 2470 - 2486.

共引文献129

同被引文献11

引证文献2

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部